Demographic and Treatment Characteristics
| . | HLA-Identical Sibling Donors . | Alternative Family Donors . | P Value* . |
|---|---|---|---|
| No. of patients | 36 | 24 | |
| Median age (range) | |||
| Patients | 43 (19-59) | 35 (3-53) | P < .003 |
| Donors | 43 (21-64) | 46 (17-78) | NS |
| Donor → recipient gender† | |||
| F → F | 7 (19%) | 3 (13%) | |
| M → M | 13 (36%) | 6 (25%) | NS |
| M → F | 6 (17%) | 5 (21%) | |
| F → M | 10 (28%) | 10 (42%) | |
| No. of HLA-A, B, DR, DQ, DP mismatches† | |||
| GVH-direction | |||
| 0 | 36 (100%) | 5 (21%) | |
| 1 | 0 | 18 (75%) | |
| 2 | 0 | 1 (4%) | |
| HVG-direction | |||
| 0 | 36 (100%) | 1 (4%) | |
| 1 | 0 | 13 (54%) | |
| 2 | 0 | 7 (29%) | |
| ≥3 | 0 | 3 (13%) | |
| Diagnosis† | |||
| Acute myeloid leukemia | 11 (31%) | 6 (25%) | |
| Acute lymphoblastic leukemia | 1 (3%) | 4 (17%) | |
| Chronic myeloid leukemia | 17 (47%) | 12 (50%) | NS |
| Myelodysplastic syndrome | 2 (6%) | 0 | |
| Multiple myeloma | 0 | 1 (4%) | |
| Non-Hodgkin's lymphoma | 4 (11%) | 0 | |
| Hodgkin's disease | 1 (3%) | 1 (4%) | |
| Disease stages† | |||
| Early stages‡ | 21 (58%) | 10 (42%) | NS |
| Advanced stages‡ | 15 (42%) | 14 (58%) | |
| GVHD prophylaxis† | |||
| Ciclosporin ± prednisolone | 6 (17%) | 2 (8%) | NS |
| Short methotrexate + ciclosporin | 30 (83%) | 22 (92%) | |
| Myeloablative regimens† | |||
| TBI + cyclophosphamide ± etoposide | 21 (58%) | 22 (92%) | P < .02 |
| Chemotherapyρ | 15 (42%) | 2 (8%) | |
| Posttransplant rhG-CSF† | |||
| Yes | 24 (67%) | 20 (83%) | NS |
| No | 12 (33%) | 4 (17%) |
| . | HLA-Identical Sibling Donors . | Alternative Family Donors . | P Value* . |
|---|---|---|---|
| No. of patients | 36 | 24 | |
| Median age (range) | |||
| Patients | 43 (19-59) | 35 (3-53) | P < .003 |
| Donors | 43 (21-64) | 46 (17-78) | NS |
| Donor → recipient gender† | |||
| F → F | 7 (19%) | 3 (13%) | |
| M → M | 13 (36%) | 6 (25%) | NS |
| M → F | 6 (17%) | 5 (21%) | |
| F → M | 10 (28%) | 10 (42%) | |
| No. of HLA-A, B, DR, DQ, DP mismatches† | |||
| GVH-direction | |||
| 0 | 36 (100%) | 5 (21%) | |
| 1 | 0 | 18 (75%) | |
| 2 | 0 | 1 (4%) | |
| HVG-direction | |||
| 0 | 36 (100%) | 1 (4%) | |
| 1 | 0 | 13 (54%) | |
| 2 | 0 | 7 (29%) | |
| ≥3 | 0 | 3 (13%) | |
| Diagnosis† | |||
| Acute myeloid leukemia | 11 (31%) | 6 (25%) | |
| Acute lymphoblastic leukemia | 1 (3%) | 4 (17%) | |
| Chronic myeloid leukemia | 17 (47%) | 12 (50%) | NS |
| Myelodysplastic syndrome | 2 (6%) | 0 | |
| Multiple myeloma | 0 | 1 (4%) | |
| Non-Hodgkin's lymphoma | 4 (11%) | 0 | |
| Hodgkin's disease | 1 (3%) | 1 (4%) | |
| Disease stages† | |||
| Early stages‡ | 21 (58%) | 10 (42%) | NS |
| Advanced stages‡ | 15 (42%) | 14 (58%) | |
| GVHD prophylaxis† | |||
| Ciclosporin ± prednisolone | 6 (17%) | 2 (8%) | NS |
| Short methotrexate + ciclosporin | 30 (83%) | 22 (92%) | |
| Myeloablative regimens† | |||
| TBI + cyclophosphamide ± etoposide | 21 (58%) | 22 (92%) | P < .02 |
| Chemotherapyρ | 15 (42%) | 2 (8%) | |
| Posttransplant rhG-CSF† | |||
| Yes | 24 (67%) | 20 (83%) | NS |
| No | 12 (33%) | 4 (17%) |
Abbreviations: HLA, human leukocyte antigen; NS, not significant; GVH, graft versus host; HVG, host versus graft; TBI, total body irradiation; rhG-CSF, recombinant human granulocyte colony-stimulating factor.
Comparisons between classified variables by Fisher's exact test; comparisons between continuous variables by Wilcoxon rank-sum test.
No. of patients (rounded % of patients).
Definitions as given in the patients and methods section.
ρ Busulfan + cyclophosphamide ± thiotepa in 14 patients; melphalan + etoposide + cytarabin + cyclophosphamide + dexamethasone in 3 patients with sibling donors.